Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Great Debates and Updates in GI Malignancies

April 3-4, 2009

New York, New York, USA

Westin New York at Times Square

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex designates this educational activity for a maximum 12.0 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for gastroenterologists, medical oncologists, radiation oncologists, hepatologists, surgeons, clinical researchers, and physicians-in-training who wish to review and update their knowledge and management of gastrointestinal malignancies.

Objectives

After attending this educational activity, participants should be able to:

Determine the benefits and risks of surgical management of gastrointestinal cancers
Summarize the role of radiotherapy in the treatment of gastrointestinal malignancies
Review the genetics of gastrointestinal cancers and applicability to patient prognosis and response to therapy
Discuss the significance and utilization of appropriate chemotherapeutic regimens in the management of colorectal cancer
Compare and contrast virtual colonoscopy with standard colonoscopy for routine screening purposes
Summarize the optimal treatment modalities for esophageal cancer and gastrointestinalstromal tumors
Evaluate currently available and emerging therapeutic approaches for locally advanced and metastatic pancreatic cancer
Discuss therapeutic options for early stage and advanced gastric carcinomas
Describe the relationship between obesity, the metabolic syndrome and cancer
Interpret and summarize significant and practice-changing data presented at the 2009 Gastrointestinal Cancers Symposium

Jaffer Ajani, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Jordan D. Berlin, MD
Vanderbilt University Medical Center
Nashville, Tennessee

Charles D. Blanke MD, FACP, FRCPC
British Columbia Cancer Agency and University of British Columbia
Vancouver, British Columbia, Canada

Michael Choti, MD, MBA
Johns Hopkins University School of Medicine
Baltimore, Maryland

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Michael G. Haddock, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Matthew Kulke, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Heinz-Josef Lenz, MD
University of Southern California
Norris Comprehensive Cancer Center
Los Angeles, California

Michael Macari, MD
New York University School of Medicine
New York, New York

Robert G. Maki, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Neal J. Meropol, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Wells Messersmith, MD, FACP
University of Colorado
Denver, Colorado

Jeffrey A. Meyerhardt, MD, MPH
Dana-Farber Cancer Institute
Boston, Massachusetts

Bruce Minsky, MD
University of Chicago Medical Center
Chicago, Illinois

Daniel J. Sargent, PhD
Mayo Clinic College of Medicine
Rochester, Minnesota

Nicholas J. Shaheen, MD, PhD
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Friday, April 3, 2009

7:00 am
Continental breakfast and registration

8:00 am
Welcome and introduction
Axel Grothey, MD - Chair
Daniel G. Haller, MD - Chair
James Epstein, MD - Moderator

8:10 am
Debate: What is the best therapeutic option for patients who present with resectable liver- only metastatic colon cancer? Chemotherapy followed by surgery
Michael Choti, MD, MBA

Surgery followed by chemotherapy
Speaker invited

8:40 am
Debate: Is pre-operative radiation therapy necessary for almost all EUS T2 rectal cancers?

Yes – Bruce Minsky, MD

No – Daniel G. Haller, MD

9:10 am
Combining chemotherapy with biologic agents in colorectal cancer-Positives, negatives, sequences versus combinations and the questions still unanswered
Axel Grothey, MD

9:45 am
Debate: For resected carcinoma of the pancreas, which adjuvant therapy will lead to the best outcome?

Systemic chemotherapy alone
Jordan D. Berlin, MD

Chemoradiation
Michael G. Haddock, MD

10:15 am Break

10:35 am
Debate: Are calcium and magnesium infusions an appropriate approach to prevention of platinum chemotherapy induced neurotoxicity? Yes – Howard S. Hochster, MD
No – Axel Grothey, MD

11:05 am
Debate: Is there a standard of care for the management of high risk resectable GIST?

Imatinib followed by surgery
Charles D. Blanke, MD, FACP, FRCPC

Surgery followed by imatinib
Robert G. Maki, MD, PhD

11:35 am
Pancreatic neuroendocrine tumors: Classification, stratification and eradication
Matthew Kulke, MD

12:05 pm
Lunch with the Professors

1:15 pm
Obesity, the metabolic syndrome and cancer in the USA
Jeffrey A. Meyerhardt, MD, MPH

1:50 pm
Debate: What is the standard of care for adjuvant therapy of resected gastric or GE junction adenocarcinoma?

Systemic chemotherapy
Jaffer Ajani, MD

Chemoradiation
David H. Ilson, MD, PhD

2:20 pm
Debate: Will increased resection rates in metastatic colon cancer following combined chemo-biologic therapy lead to improved long term survival?
Michael Choti, MD, MBA

2:50 pm
Challenging cases in GI cancer

Case One - Esophageal Cancer

Case Two - Advanced Gastric Cancer

Case Three - GIST

3:45 pm
Adjourn

Saturday, April 4, 2009

7:00 am
Continental breakfast and registration

8:00 am
Welcome and introduction
Axel Grothey, MD - Chair
Daniel G. Haller, MD - Chair
James Epstein, MD - Moderator

8:10 am
Molecular sub-typing in colorectal cancer: Kras and beyond
Heinz- Josef Lenz, MD

8:50 am
Debate: Should gemcitabine remain the standard of care and the main comparator in clinical trials for advanced pancreatic cancer?

Yes – Daniel G. Haller, MD

No – Jordan D. Berlin, MD

9:20 am
Debate: What is the standard of care for squamous cell carcinoma of the esophagus?

Chemoradiation alone
David H. Ilson, MD, PhD

Chemoradiation followed by surgery
Michael G. Haddock, MD

9:50 am
Break

10:10 am
GI clinical trials in the age of biomarkers
Daniel J. Sargent, PhD

10:40 am
Highlights from the Gastrointestinal Cancers Symposium 2009 Early stage colorectal cancers
Daniel G. Haller, MD

Advanced colorectal cancers
Axel Grothey, MD

Upper GI malignancies
Jaffer Ajani, MD

Pancreatic and hepatobiliary cancers
David H. Ilson, MD, PhD

12:10 pm
Lunch with the Professors

1:20 pm
Pharmacoeconomics - Can we afford the cancer care of the future?
Neal J. Meropol, MD

1:50 pm
Debate: Can virtual colonoscopy replace standard colonoscopy for routine screening purposes?

Yes – Michael Macari, MD

No – Nicholas J. Shaheen, MD, PhD

2:20 pm
GERD and Barrett’s esophagus: Incidence, surveillance and risk of progression to cancer
Nicholas J. Shaheen, MD, MPh

2:50 pm
Challenging cases in GI cancers

Case One - Pancreatic Cancer

Case Two - Metastatic Colorectal Cancer

Case Three - Rectal Cancer

3:45 pm
Adjourn

Registration Fees

Physicians........................................................$150

Nurses, Fellows, Residents*...............................$75
*proof of eligibility must accompany registration

Pharmaceutical Industry.................................... $175

To Register:

You may register online by Thursday, March 26, 2009 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

Payment:

To pre-register, registration and payment must be received no later than Thursday, March 26, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation:

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than Thursday, March 26, 2009. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after Thursday, March 26, 2009. Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
http://www.starwoodmeeting.com/Book/greatdebates

The Westin New York at Times Square is located at 43rd Street and 8th Avenue, in the heart of the Broadway District with 40 theatres within walking distance. It is surrounded by the New York fashion, financial and commercial districts with easy access to the city’s subway system and within blocks of Penn Station and Grand Central Station. It is close to spectacular sights, city landmarks and incredible shopping.

For the convenience of attendees, a limited number of rooms have been reserved until March 12, 2009 at a discounted rate of $339.00 single/double occupancy, plus tax, currently at 13.375% plus $3.50 (NY City Occupancy Tax/Javits Center fee). This rate is not guaranteed outside the conference dates or after March 12, 2009.

To reserve your room please contact The Westin New York at Times Square reservations department at 1 (800) 937 8461. To receive the group rate, callers must identify themselves as being with the Great Debates in GI Malignancies group. Internet users must copy and paste the following link into a web browser: http://www.starwoodmeeting.com/book/greatdebates. Reservation requests received after March 12, 2009 may not be guaranteed the group rate. Reservations requests received after March 12, 2009, will be accepted on a space available basis at the hotel’s published rates. Guest wishing to avoid an early departure fee of $100 must advise the hotel at or before check-in of any changes in the length of stay.

Invitation

Dear Colleagues

We invite you to join us in New York City this April for Great Debates and Updates in GI Malignancies. This meeting is a different kind of educational event – one we know you will enjoy and learn from. Recognized thought leaders will engage in lively and interactive debates over some of the most controversial topics in the field and offer selected didactic presentations on the latest developments in colorectal cancer, GIST, pancreatic cancer, upper GI malignancies and more. Faculty and audience discussion will be encouraged with a focus on how new information fits into current community practice in the field, providing you with the opportunity to learn how experts in the field manage their patients. The unique and instructive format of Great Debates and Updates in GI Malignancies will keep you up to date in the field and give you expert insight into the management of your GI patients.

We hope to see you there!

Axel Grothey, MD
Daniel G. Haller, MD
Conference chairs

High praise from past participants:

“The consensus was that this was the best educational event that happened all year.”

“I thought the conference was excellent”

“This was one of the most informative meetings I have attended recently. The debate format was excellent. I also like the audience participation.”

“An outstanding format,great lectures and discussions. The quality of the meeting was of such a high caliber.”

Important Dates

Hotel Reservation Deadline
Thursday, March 12, 2009

Pre-Registration Deadline
Thursday, March 26, 2009

Conference Dates
April 3-4, 2009

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Chairs:

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

Moderator:

James Epstein, MD
Senior Medical Advisor
Imedex, LLC
Alpharetta, Georgia

Conference Location

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701

The Registration and Information Desk will be staffed:

Friday
April 3, 2009
7:00 am – 4:00 pm

Saturday
April 4, 2009
7:00 am – 4:00 pm

Audience Participation....

A Hands-On Experience During the scientific sessions, speakers and the audience can exchange information through a “hands-on” computerized speaker-audience interaction system.With this state-of-the-art equipment, participants answer multiple choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system maximizes the ability for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

Platinum

Genentech BioOncology

Silver

Pfizer

Bronze

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.